Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease

被引:18
|
作者
Mendoza, Yuly [1 ]
Cocciolillo, Sila [2 ]
Chen, Tianyan [1 ]
Margini, Cristina [2 ]
Sebastiani, Giada [1 ]
Berzigotti, Annalisa [2 ]
Murgia, Giuseppe [1 ]
机构
[1] Univ Bern, Bern Univ Hosp, Inselspital, Univ Clin Visceral Surg & Med,Dept Biomed Res, Bern, Switzerland
[2] McGill Univ, Royal Victoria Hosp, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
关键词
Cirrhosis; Ultrasound; NASH; Fibrosis; CONTROLLED ATTENUATION PARAMETER; STIFFNESS MEASUREMENT; RISK; COMPLICATIONS; PREDICTION; FIBROSIS;
D O I
10.1016/j.cgh.2020.04.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Some patients with compensated advanced chronic liver disease (cACLD) require use of an extralarge probe for liver stiffness measurement (LSM), owing to overweight or obesity. However, the ability of noninvasive markers of portal hypertension and the controlled attenuation parameter (CAP) to determine which of these patients are at risk for decompensation has not been fully assessed. METHODS: We collected data from 272 patients with cACLD (LSM double dagger 10 kPa by XL probe; 57% with nonalcoholic steatohepatitis; mean body mass index, 33.8 6.5 kg/m2; median Child-Pugh score, 5; median LSM, 16.8 kPa; mean CAP, 318 66 dB/m) evaluated at 2 academic centers from 2015 through 2018. We collected clinical data on decompensation (ascites, portal hypertension bleeding, jaundice, hepatic encephalopathy) and severe bacterial infections; patients were followed up for a median of 17 months (interquartile range, 11-24 mo). We evaluated associations between these events and LSM, CAP, LSM*spleen size/platelet count (LSPS), and portal hypertension risk scores. RESULTS: Decompensation occurred in 12 patients and severe bacterial infections developed in 5 patients. LSM, LSPS, and the portal hypertension risk score identified patients with decompensation with area under the receiver operating characteristic curve values of 0.848 (95% CI, 0.720-0.976; P < .0001), 0.881 (95% CI, 0.798-0.954; P < .0001), and 0.890 (95% CI, 0.814-0.966; P < .0001), respectively. In multivariate Cox regression analysis, in patients with nonalcoholic steatohepatitis, LSM and CAP were associated independently with decompensation and severe bacterial infection; CAP >= 220 dB/m was associated with a reduced risk of decompensation (hazard ratio, 0.043, 95% CI, 0.004-0.476; P =.01). CONCLUSIONS: LSM, LSPS, and the portal hypertension risk score identify obese or overweight patients with cACLD who are at increased risk of decompensation and severe bacterial infection.
引用
收藏
页码:3017 / +
页数:15
相关论文
共 50 条
  • [1] Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
    Pons, Monica
    Augustin, Salvador
    Scheiner, Bernhard
    Guillaume, Maeva
    Rosselli, Matteo
    Rodrigues, Susana G.
    Stefanescu, Horia
    Ma, Mang M.
    Mandorfer, Mattias
    Mergeay-Fabre, Mayka
    Procopet, Bogdan
    Schwabl, Philipp
    Ferlitsch, Arnulf
    Semmler, Georg
    Berzigotti, Annalisa
    Tsochatzis, Emmanuel
    Bureau, Christophe
    Reiberger, Thomas
    Bosch, Jaime
    Abraldes, Juan G.
    Genesca, Joan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (04): : 723 - 732
  • [2] Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease
    Vuille-Lessard, Elise
    Rodrigues, Susana G.
    Berzigotti, Annalisa
    CLINICS IN LIVER DISEASE, 2021, 25 (02) : 253 - 289
  • [3] FIB-4 improves LSM-based prediction of clinical decompensation in overweight or obese patients with compensated advanced chronic liver disease
    Mendoza, Yuly Paulin
    Shengir, Mohamed
    Bosch, Jaime
    Sebastiani, Giada
    Berzigotti, Annalisa
    JOURNAL OF HEPATOLOGY, 2021, 75 : S373 - S373
  • [4] Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update
    Ravaioli, Federico
    Montagnani, Marco
    Lisotti, Andrea
    Festi, Davide
    Mazzella, Giuseppe
    Azzaroli, Francesco
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2018, 2018
  • [5] Individualization of HCC and Portal Hypertension Surveillance in Patients with Compensated Advanced Chronic Liver Disease and SVR
    Mandorfer, Mattias
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (01) : 14 - 15
  • [6] Individualization of HCC and Portal Hypertension Surveillance in Patients with Compensated Advanced Chronic Liver Disease and SVR
    Mattias Mandorfer
    Digestive Diseases and Sciences, 2023, 68 : 14 - 15
  • [7] METABONOMICS AND METAGENOMICS FOR DIAGNOSIS OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN PATIENTS WITH COMPENSATED ADVANCED CHRONIC LIVER DISEASE
    Zhou Tiantian
    Hu Han
    Lai Wei
    He Jinjing
    Yu Sicheng
    Gao Xiang
    Zhu Jie
    Yan Huadong
    HEPATOLOGY, 2024, 80 : S78 - S79
  • [8] Secondary hyperaldosteronism and liver fibrosis in patients with compensated chronic liver disease or portal hypertension
    Vitale, Giovanni
    Coscia, Kimberly
    Zavatta, Guido
    Morelli, Maria Cristina
    Vicennati, Valentina
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 99 : 118 - 120
  • [9] Robustness of Liver Stiffness-Based Model for Portal Hypertension in Compensated Advanced Chronic Liver Disease
    Chen, Guofeng
    An, Weimin
    Ji, Dong
    Du, Xiaoxue
    Liu, Changchun
    Huang, Yifei
    Liu, Chuan
    Qi, Xiaolong
    HEPATOLOGY, 2018, 68 : 480A - 481A
  • [10] Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension
    Pastrovic, Frane
    Novak, Rudjer
    Grgurevic, Ivica
    Hrkac, Stela
    Salai, Grgur
    Zarak, Marko
    Grgurevic, Lovorka
    PLOS ONE, 2024, 19 (04):